08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold
Relateret debat
19 jul - 
Ja de har da lavet to kontrakter - så må vi se med de t..
19 jul - 
ja Bavarian er heldigvis os partner med J&J. De er efte..
19 jul - 
Står der noget i regnskabet omkring udviklingen på Ebol..

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Bavarian/dir.: Gul feber-vaccine er et forsøg med lille profit

27-07-2016 16:12:59
Det er et gratis studie - endda med lidt lommepenge - når Bavarian skal gennemføre et fase 1-forsøg med sin vaccine mod gul feber på bestilling af et institut u..

Finsk FLSmidth-konkurrent mærker resultatdyk på alle poster -NY

27-07-2016 12:19:46
Andet kvartal viste med al tydelighed de hårde tider, Outotec er oppe imod. Det finske industriselskab, som blandt andet konkurrerer med danske FLSmidth inden f..

Aktier/åbning: ALK styrter efter skidt nyt i grønt marked

27-07-2016 09:31:21
De danske C20 aktier stiger ved åbningen onsdag, men det er særligt uden for C20, at der sker ting og sager.ALK-aktien falder massivt efter at have oplyst, at s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-konkurrent opjusterer efter stor fremgang
2
Aktier/åbning: ALK styrter efter skidt nyt i grønt marked
3
Aktier/middag: Amerikansk kindhest lammer ALK-Abelló
4
Veloxis-aktien bragede 11 pct. frem oven på generalforsamling
5
Bavarian/dir.: Gul feber-vaccine er et forsøg med lille profit

Relaterede aktiekurser

Johnson & Johnson 124,77 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. juli 2016 08:38:26
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160727.4 - EUROWEB1 - 2016-07-28 08:38:26 - 2016-07-28 08:38:26 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x